Step 1: Understanding the Concept:
Glycosides are organic compounds composed of a sugar portion (glycone) and a non-sugar portion (aglycone) bound together by a glycosidic bond.
In pharmacology, cardiac glycosides are a specific therapeutic class of glycosides used to treat congestive heart failure.
Step 2: Detailed Explanation:
Let us analyze the classification of each drug:
- Digitoxin: A cardiotonic steroid glycoside obtained from the foxglove plant, *Digitalis purpurea*.
- Digoxin: A widely used cardiac glycoside isolated from *Digitalis lanata*.
- Ouabain: A highly potent, fast-acting cardiac glycoside obtained from the seeds of *Strophanthus gratus*.
- Glycyrrhizin: The principal sweet-tasting compound of licorice root (*Glycyrrhiza glabra*).
While chemically a triterpenoid saponin glycoside, in clinical veterinary pharmacology, it is not grouped under the standard therapeutic glycosides (cardiac glycosides) used for cardiovascular therapy.
Step 3: Final Answer:
Therefore, Glycyrrhizin is the drug that does not belong to the primary therapeutic cardiac glycoside group.